Literature DB >> 16113254

Sequence variation and immunologic cross-reactivity among Babesia bovis merozoite surface antigen 1 proteins from vaccine strains and vaccine breakthrough isolates.

Tanya Leroith1, Kelly A Brayton, John B Molloy, Russell E Bock, Stephen A Hines, Ala E Lew, Terry F McElwain.   

Abstract

The Babesia bovis merozoite surface antigen 1 (MSA-1) is an immunodominant membrane glycoprotein that is the target of invasion-blocking antibodies. While antigenic variation has been demonstrated in MSA-1 among strains from distinct geographical areas, the extent of sequence variation within a region where it is endemic and the effect of variation on immunologic cross-reactivity have not been assessed. In this study, sequencing of MSA-1 from two Australian B. bovis vaccine strains and 14 breakthrough isolates from vaccinated animals demonstrated low sequence identity in the extracellular region of the molecule, ranging from 19.8 to 46.7% between the T vaccine strain and eight T vaccine breakthrough isolates, and from 18.7 to 99% between the K vaccine strain and six K vaccine breakthrough isolates. Although MSA-1 amino acid sequence varied substantially among strains, overall predicted regions of hydrophilicity and hydrophobicity in the extracellular domain were conserved in all strains examined, suggesting a conserved functional role for MSA-1 despite sequence polymorphism. Importantly, the antigenic variation created by sequence differences resulted in a lack of immunologic cross-reactivity among outbreak strains using sera from animals infected with the B. bovis vaccine strains. Additionally, sera from cattle hyperinfected with the Mexico strain of B. bovis and shown to be clinically immune did not cross-react with MSA-1 from any other isolate tested. The results indicate that isolates of B. bovis capable of evading vaccine-induced immunity contain an msa-1 gene that is significantly different from the msa-1 of the vaccine strain, and that the difference can result in a complete lack of cross-reactivity between MSA-1 from vaccine and breakthrough strains in immunized animals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113254      PMCID: PMC1231062          DOI: 10.1128/IAI.73.9.5388-5394.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

Review 1.  Designing blood-stage vaccines against Babesia bovis and B. bigemina.

Authors:  W C Brown; G H Palmer
Journal:  Parasitol Today       Date:  1999-07

2.  Generation of a mosaic pattern of diversity in the major merozoite-piroplasm surface antigen of Theileria annulata.

Authors:  M J Gubbels; F Katzer; G Hide; F Jongejan; B R Shiels
Journal:  Mol Biochem Parasitol       Date:  2000-09       Impact factor: 1.759

3.  The Babesia bovis merozoite surface antigen 2 locus contains four tandemly arranged and expressed genes encoding immunologically distinct proteins.

Authors:  Monica Florin-Christensen; Carlos E Suarez; Stephen A Hines; Guy H Palmer; Wendy C Brown; Terry F McElwain
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

4.  Babesia bovis: common protein fractions recognized by oligoclonal B. bovis-specific CD4+ T cell lines from genetically diverse cattle.

Authors:  R W Stich; A C Rice-Ficht; W Tuo; W C Brown
Journal:  Exp Parasitol       Date:  1999-01       Impact factor: 2.011

5.  Cloning of Babesia bovis by in vitro cultivation.

Authors:  S D Rodriguez; G M Buening; T J Green; C A Carson
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

6.  Molecular basis for variable expression of merozoite surface antigen gp45 among American isolates of Babesia bigemina.

Authors:  T G Fisher; T F McElwain; G H Palmer
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

7.  Immunization of cattle with recombinant Babesia bovis merozoite surface antigen-1.

Authors:  S A Hines; G H Palmer; D P Jasmer; W L Goff; T F McElwain
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  Cross-protective immunity induced by Babesia bovis clones with antigenically unrelated variable merozoite surface antigens.

Authors:  V Shkap; E Pipano; T F McElwain; U Herzberg; Y Krigel; L Fish; G H Palmer
Journal:  Vet Immunol Immunopathol       Date:  1994-06       Impact factor: 2.046

9.  Babesia bovis: continuous cultivation in a microaerophilous stationary phase culture.

Authors:  M G Levy; M Ristic
Journal:  Science       Date:  1980-03-14       Impact factor: 47.728

10.  Investigations of breakdowns in protection provided by living Babesia bovis vaccine.

Authors:  R E Bock; A J de Vos; T G Kingston; I A Shiels; R J Dalgliesh
Journal:  Vet Parasitol       Date:  1992-06       Impact factor: 2.738

View more
  15 in total

1.  Arboprotozoae.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

2.  Merozoite surface antigen 2 proteins of Babesia bovis vaccine breakthrough isolates contain a unique hypervariable region composed of degenerate repeats.

Authors:  Shawn J Berens; Kelly A Brayton; John B Molloy; Russell E Bock; Ala E Lew; Terry F McElwain
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

3.  The Babesia bovis merozoite surface antigen 1 hypervariable region induces surface-reactive antibodies that block merozoite invasion.

Authors:  Tanya LeRoith; Shawn J Berens; Kelly A Brayton; Stephen A Hines; Wendy C Brown; Junzo Norimine; Terry F McElwain
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Association and evidence for linked recognition of type IV secretion system proteins VirB9-1, VirB9-2, and VirB10 in Anaplasma marginale.

Authors:  Kaitlyn Morse; Junzo Norimine; Guy H Palmer; Eric L Sutten; Timothy V Baszler; Wendy C Brown
Journal:  Infect Immun       Date:  2011-10-28       Impact factor: 3.441

5.  Tick passage results in enhanced attenuation of Babesia bovis.

Authors:  Kerry S Sondgeroth; Terry F McElwain; Massaro W Ueti; Glen A Scoles; Kathryn E Reif; Audrey O T Lau
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

6.  Genetic diversity of Babesia bovis in beef cattle in a large wetland in Brazil.

Authors:  Natalia Serra Mendes; Inalda Angélica de Souza Ramos; Heitor Miraglia Herrera; João Bosco Vilela Campos; João Victor de Almeida Alves; Gabriel Carvalho de Macedo; Rosangela Zacarias Machado; Marcos Rogério André
Journal:  Parasitol Res       Date:  2019-05-11       Impact factor: 2.289

7.  Expression, Purification, and Biological Characterization of Babesia microti Apical Membrane Antigen 1.

Authors:  Prasun Moitra; Hong Zheng; Vivek Anantharaman; Rajdeep Banerjee; Kazuyo Takeda; Yukiko Kozakai; Timothy Lepore; Peter J Krause; L Aravind; Sanjai Kumar
Journal:  Infect Immun       Date:  2015-07-20       Impact factor: 3.441

8.  Coinfection with antigenically and genetically distinct virulent strains of Babesia bovis is maintained through all phases of the parasite life cycle.

Authors:  Shawn J Berens; Kelly A Brayton; Terry F McElwain
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

9.  Anaplasma marginale type IV secretion system proteins VirB2, VirB7, VirB11, and VirD4 are immunogenic components of a protective bacterial membrane vaccine.

Authors:  Eric L Sutten; Junzo Norimine; Paul A Beare; Robert A Heinzen; Job E Lopez; Kaitlyn Morse; Kelly A Brayton; Joseph J Gillespie; Wendy C Brown
Journal:  Infect Immun       Date:  2010-01-11       Impact factor: 3.441

10.  Genotypic diversity of merozoite surface antigen 1 of Babesia bovis within an endemic population.

Authors:  Audrey O T Lau; Karla Cereceres; Guy H Palmer; Debbie L Fretwell; Monica J Pedroni; Juan Mosqueda; Terry F McElwain
Journal:  Mol Biochem Parasitol       Date:  2010-04-03       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.